Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) just unveiled an update.
Shanghai Junshi Biosciences has obtained regulatory acceptance from the National Association of Financial Market Institutional Investors for the registration of up to RMB20 billion in medium-term technology innovation bonds, which will be underwritten by Bank of Shanghai and remain valid for issuance over a two-year period. The company plans to issue these bonds in tranches based on its capital needs and market conditions, potentially strengthening its funding capacity for innovation-driven projects, while cautioning investors that the bond issuance may or may not proceed and that results will be disclosed through officially recognized channels.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$21.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong that focuses on innovative drug research and development, particularly in cutting-edge biomedical and biotechnology fields, targeting both domestic and international healthcare markets.
Average Trading Volume: 3,597,136
Technical Sentiment Signal: Sell
Current Market Cap: HK$35.58B
For an in-depth examination of 1877 stock, go to TipRanks’ Overview page.